Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBINASDAQ:CGTXNASDAQ:PASGNASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIBrickell Biotech$0.86$2.21▼$37.35$6.75M0.02206,730 shs31,300 shsCGTXCognition Therapeutics$0.30$0.33$0.22▼$2.54$18.60M0.752.75 million shs2.32 million shsPASGPassage Bio$0.33-7.3%$0.37$0.26▼$1.33$21.85M1.71368,089 shs534,784 shsPLURPluri$5.30+19.9%$4.75$3.33▼$7.13$34.62M0.7720,102 shs466,303 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIBrickell Biotech0.00%0.00%0.00%0.00%0.00%CGTXCognition Therapeutics+15.61%+7.14%+1.04%-32.07%-83.78%PASGPassage Bio+5.02%-7.60%-4.97%-23.58%-61.36%PLURPluri+0.68%+4.25%-3.07%+0.66%-10.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIBrickell BiotechN/AN/AN/AN/AN/AN/AN/AN/ACGTXCognition Therapeutics3.1032 of 5 stars3.55.00.00.00.61.71.3PASGPassage Bio2.2541 of 5 stars3.52.00.00.00.61.71.3PLURPluri1.789 of 5 stars3.53.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIBrickell Biotech 0.00N/AN/AN/ACGTXCognition Therapeutics 3.00Buy$5.631,775.00% UpsidePASGPassage Bio 3.00Buy$7.502,200.61% UpsidePLURPluri 3.00Buy$12.00126.42% UpsideCurrent Analyst Ratings BreakdownLatest BBI, PLUR, CGTX, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.006/2/2025PLURPluriIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.006/2/2025PLURPluriAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.005/27/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.005/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIBrickell Biotech$4.64M0.00N/AN/A$9.75 per share0.00CGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/APASGPassage BioN/AN/AN/AN/A$0.99 per shareN/APLURPluri$330K125.75N/AN/A$1.00 per share5.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIBrickell Biotech-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/ACGTXCognition Therapeutics-$33.97M-$0.74N/AN/AN/AN/A-194.42%-115.14%8/6/2025 (Estimated)PASGPassage Bio-$64.77M-$1.02N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)PLURPluri-$20.89M-$5.53N/A∞N/A-2,563.29%-4,191.91%-85.40%N/ALatest BBI, PLUR, CGTX, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PASGPassage Bio-$0.24-$0.25-$0.01-$0.25N/AN/A5/13/2025Q3 2025PLURPluriN/A-$0.94N/A-$0.94N/A$0.43 million5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12-$0.14-$0.02-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIBrickell BiotechN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIBrickell BiotechN/A6.366.36CGTXCognition TherapeuticsN/A2.092.09PASGPassage BioN/A3.743.74PLURPluri51.654.814.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIBrickell BiotechN/ACGTXCognition Therapeutics43.35%PASGPassage Bio53.48%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipBBIBrickell Biotech4.53%CGTXCognition Therapeutics14.40%PASGPassage Bio5.00%PLURPluri25.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIBrickell Biotech162.87 million2.74 millionNot OptionableCGTXCognition Therapeutics2061.99 million53.07 millionNot OptionablePASGPassage Bio13062.15 million59.04 millionOptionablePLURPluri1507.83 million5.80 millionOptionableBBI, PLUR, CGTX, and PASG HeadlinesRecent News About These CompaniesAlliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy RecommendationJune 2, 2025 | msn.comPluri Inc. reschedules 2025 annual meetingMay 27, 2025 | investing.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27, 2025 | prnewswire.comBrainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plansMay 19, 2025 | msn.comPluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.May 16, 2025 | finanznachrichten.dePluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market ExpansionMay 16, 2025 | tmcnet.comPluri: Fiscal Q3 Earnings SnapshotMay 13, 2025 | timesunion.comTPluri Inc. acquires majority stake in Kokomodo Ltd.April 30, 2025 | uk.investing.comPluri acquires 71% stake in KokomodoApril 29, 2025 | foodbusinessnews.netFPluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.April 28, 2025 | globenewswire.comPluri Inc. enters agreement, issues pre-funded warrantsApril 27, 2025 | investing.comUkraine gains access to Israeli anti-radiation drug amid nuclear threatsApril 21, 2025 | msn.comUkraine prepares for nuclear emergency - Israel to help save thousandsApril 21, 2025 | msn.comIn case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatmentApril 20, 2025 | msn.comInnovative Treatment Aims to Protect Ukrainians from Nuclear Radiation ThreatApril 17, 2025 | themunicheye.comTPluri announces USPTO issued patent covering its immune cell expansion techApril 12, 2025 | markets.businessinsider.comPluri’s immune cell expansion technologies gain patentsApril 11, 2025 | finance.yahoo.comPluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and IsraelApril 10, 2025 | finance.yahoo.comUsing cell science to fight nuclear weapons: How is Pluri revolutionizing health and food tech?March 14, 2025 | msn.comPluri announces exclusive collaboration agreement with HemafundMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBI, PLUR, CGTX, and PASG Company DescriptionsBrickell Biotech NASDAQ:BBIBrickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.Cognition Therapeutics NASDAQ:CGTX$0.30 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$0.30 +0.00 (+0.33%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Passage Bio NASDAQ:PASG$0.33 -0.03 (-7.28%) Closing price 04:00 PM EasternExtended Trading$0.35 +0.02 (+7.06%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Pluri NASDAQ:PLUR$5.30 +0.88 (+19.91%) Closing price 04:00 PM EasternExtended Trading$5.04 -0.26 (-4.91%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
